Global Neurodegenerative Disorder Therapeutics Market

Focus on Product, Mechanism, Route of Administration, Indication, Country Data (14 Countries), and Competitive Landscape - Analysis and Forecast, 2019-2030

Published Year: 2020
SKU: BHL0960SA

3250

Online Access for 1-3 Users. Permission to Print.


In case you require a hard copy, there will be an additional charge of $500. Please email us at [email protected] with your request.

A quick peek into the report

Table of Contents

Download this TOC  

Request a Sample

1 Technology Definition

1.1    Inclusion and Exclusion Criteria
         1.1.1    Inclusions
         1.1.2    Exclusions

2 Research Scope

2.1    Key Questions Answered in the Report

3 Research Methodology

3.1    Neurodegenerative Disorder Therapeutics: Research Methodology
3.2    Primary Data Sources
3.3    Secondary Data Sources
3.4    Market Estimation Model
3.5    Criteria for Company Profiling

4 Market Overview

4.1    Neurodegenerative Disorder Therapeutics and Its Clinical Importance
4.2    Neurodegenerative Disorder Therapeutics Development and Commercialization Landscape
4.3    Global Neurodegenerative Disorder Therapeutics Market and Growth Potential, 2019-2030
4.4    Pricing and Reimbursement Scenario
4.5    Impact of Patent Expiry and Entry of Biosimilars on Market
4.6    Impact of COVID-19 on Neurodegenerative Disorder Therapeutics Market

5 Epidemiology of Neurodegenerative Disorder Therapeutics

Epidemiology of Neurodegenerative Disorder Therapeutics

6 Patent Landscape

Patent Landscape

7 Market Dynamics

7.1    Overview
7.2    Impact Analysis
7.3    Drivers
         7.3.1    Rising Global Prevalence of Neurodegenerative Disorders
         7.3.2    The Increase in Number of Geriatric Populations
         7.3.3    Increasing Research Funding in Neurodegenerative Disorders
         7.3.4    Rising Awareness about Neurodegenerative Disorders
7.4    Restraints
         7.4.1    High Failure Rate of Neurodegenerative Drugs in Clinical Trials
         7.4.2    Lack of Effective Drugs and Therapies
7.5    Opportunities

8 Industry Insights

8.1    Overview
8.2    Regulatory Scenario
8.3    Legal Requirements and Frameworks in the U.S.
         8.3.1    Clinical Trial Authorization
         8.3.2    Marketing Authorization
         8.3.3    USFDA Guidelines for BLA Submission
         8.3.4    Post-Authorization Regulations
8.4    Legal Requirements and Frameworks in Europe
         8.4.1    EMA Biologics License Application Process
         8.4.2    Centralized Procedure
         8.4.3    Decentralized Procedure
         8.4.4    Mutual-Recognition Procedure
         8.4.5    National Procedure
8.5    Legal Requirements and Frameworks in Asia-Pacific
         8.5.1    China
         8.5.2    Japan
8.6    Expedited Regulatory Designations Around the World
8.7    Role of Regulatory Bodies and Consortium in Neurodegenerative Disorder Therapeutics
8.8    Regulatory Guidelines
         8.8.1    Terminology Applied in Current Regulatory Guidelines for Development of Drugs to Treat Neurodegenerative Disorders
         8.8.2    Actionable Recommendations
                     8.8.2.1    EU:
                     8.8.2.2    EU:
                     8.8.2.3    Both Regions:
8.9    Regulatory Challenges
8.10    Reimbursement and Market Access

9 Global Neurodegenerative Disorder Therapeutics Market, by Product Type ($Million), 2019-2030

9.1    Commercialized Therapeutics
         9.1.1    Multiple Sclerosis
                     9.1.1.1    Tecfidera
                     9.1.1.2    Ocrevus
                     9.1.1.3    Gilenya
                     9.1.1.4    Aubagio
                     9.1.1.5    Interferon (Avonex and Plegridy)
                     9.1.1.6    Tysabri
                     9.1.1.7    Rebif
                     9.1.1.8    Copaxone
                     9.1.1.9    Betaseron
                     9.1.1.10    Lemtrada
                     9.1.1.11    Mavenclad
                     9.1.1.12    Fampyra
                     9.1.1.13    Ampyra
                     9.1.1.14    Mayzent
                     9.1.1.15    Vumerity
                     9.1.1.16    Others
         9.1.2    Epilepsy
                     9.1.2.1    Lyrica
                     9.1.2.2    Vimpat
                     9.1.2.3    Onfi
                     9.1.2.4    Keppra
                     9.1.2.5    Sabril
                     9.1.2.6    Briviact
                     9.1.2.7    Fycompa
                     9.1.2.8    Banzel
                     9.1.2.9    Others
         9.1.3    Alzheimer’s Market
                     9.1.3.1    Ebixa
                     9.1.3.2    Namenda XR
                     9.1.3.3    Namzaric
                     9.1.3.4    Galantamine
                     9.1.3.5    Others
         9.1.4    Parkinson’s Disease
                     9.1.4.1    Azilect
                     9.1.4.2    Neupro
                     9.1.4.3    Madopar
                     9.1.4.4    Duopa
                     9.1.4.5    Inbrija
                     9.1.4.6    Others
         9.1.5    Spinal Muscular Atrophy (SMA)
                     9.1.5.1    Spinraza
                     9.1.5.2    Zolgensma
                     9.1.5.3    Others
         9.1.6    Huntington’s Disease
                     9.1.6.1    Austedo
                     9.1.6.2    Xenazine
                     9.1.6.3    Others
9.2    Pipeline Therapeutics
         9.2.1    Multiple Sclerosis
                     9.2.1.1    Zeposia
                     9.2.1.2    Ponesimod
                     9.2.1.3    Ofatumumab
                     9.2.1.4    Ublituximab
                     9.2.1.5    Ibudilast
                     9.2.1.6    SAR442168
         9.2.2    Alzheimer’s Disease
                     9.2.2.1    Tricaprilin
                     9.2.2.2    Bryostatin-1
                     9.2.2.3    AGB101
                     9.2.2.4    COR388
                     9.2.2.5    TRx0237
                     9.2.2.6    Brexpiprazole
                     9.2.2.7    Semorinemab
                     9.2.2.8    Aducanumab
         9.2.3    Parkinson’s Disease
                     9.2.3.1    Eltoprazine
                     9.2.3.2    Ongentys
                     9.2.3.3    IPX-066
                     9.2.3.4    Xadago
                     9.2.3.5    Nourianz
                     9.2.3.6    Opicapone
         9.2.4    Huntington’s Disease
                     9.2.4.1    RG6042/IONIS -HTTrx
                     9.2.4.2    WVE-120101
                     9.2.4.3    WVE-120102

10 Global Neurodegenerative Disorder Therapeutics Market, by Drug Class ($Million), 2019-2030

10.1    Introduction
10.2    Immunomodulators
10.3    Interferons
10.4    Dopamine Agonists
10.5    Decarboxylase Inhibitors
10.6    Others

11 Global Neurodegenerative Disorder Therapeutics Market, by Indication ($Million), 2019-2030

11.1    Overview
11.2    Multiple Sclerosis
11.3    Epilepsy
11.4    Spinal Muscular Atrophy (SMA)
11.5    Alzheimer’s Disease
11.6    Parkinson’s Disease
11.7    Huntington’s Disease
11.8    Other Neurological Disorders

12 Global Neurodegenerative Disorder Therapeutics Market, by Route of Drug Administration ($Million), 2019-2030

12.1    Introduction
12.2    Oral
12.3    Injectable
12.4    Enteral
12.5    Transdermal
12.6    Others

13 Global Neurodegenerative Disorder Therapeutics Market, by Region ($Million), 2019-2030

13.1    Overview
13.2    North America
           13.2.1    U.S.
                         13.2.1.1    U.S. Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
           13.2.2    Canada
                         13.2.2.1    Canada Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
13.3    Europe
           13.3.1    Germany
                         13.3.1.1    Germany Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
           13.3.2    U.K.
                         13.3.2.1    U.K. Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
           13.3.3    France
                         13.3.3.1    France Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
           13.3.4    Italy
                         13.3.4.1    Italy Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
           13.3.5    Spain
                         13.3.5.1    Spain Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
           13.3.6    Rest-of-Europe
                         13.3.6.1    RoE Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
13.4    Asia-Pacific
           13.4.1    China
                         13.4.1.1    China Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
           13.4.2    Japan
                         13.4.2.1    Japan Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
           13.4.3    India
                         13.4.3.1    India Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
           13.4.4    South Korea
                         13.4.4.1    South Korea Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
           13.4.5    Australia
                         13.4.5.1    Australia Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
           13.4.6    Rest-of-APAC
                         13.4.6.1    RoAPAC Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
13.5    Latin America
           13.5.1    Brazil
                         13.5.1.1    Brazil Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
           13.5.2    Mexico
                         13.5.2.1    Mexico Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
           13.5.3    Rest-of-Latin America
                         13.5.3.1    RoLATAM Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
13.6    Rest-of-the-World

14 Competitive Landscape

14.1    Key Developments and Strategies
           14.1.1    Regulatory and Legal Developments
           14.1.2    Partnerships, Alliances, and Business Expansions
           14.1.3    M&A Activities
           14.1.4    Funding Activities
14.2    Market Share Analysis

15 Company Profiles

15.1    Overview
15.2    AbbVie Inc.
           15.2.1    Company Overview
           15.2.2    Role of AbbVie Inc. in Global Neurodegenerative Disorder Therapeutics Market
           15.2.3    Financials
           15.2.4    Key Insights about Financial Health of the Company
           15.2.5    SWOT Analysis
15.3    Bayer AG
           15.3.1    Company Overview
           15.3.2    Role of Bayer AG in Global Neurodegenerative Disorder Therapeutics Market
           15.3.3    Financials
           15.3.4    Key Insight about Financial Health of the Company
           15.3.5    SWOT Analysis
15.4    Biogen Inc.
           15.4.1    Company Overview
           15.4.2    Role of Biogen Inc. in Global Neurodegenerative Disorder Therapeutics Market
           15.4.3    Financials
           15.4.4    Key Insights about Financial Health of the Company
           15.4.5    SWOT Analysis
15.5    Bristol-Myers Squibb Company
           15.5.1    Company Overview
           15.5.2    Role of Bristol Myers Squibb Company in Global Neurodegenerative Disorder Therapeutics Market
           15.5.3    Financials
           15.5.4    Key Insights About Financial Health of the Company
           15.5.5    SWOT Analysis
15.6    C. H. Boehringer Sohn AG & Co. KG
           15.6.1    Company Overview
           15.6.2    Role of C. H. Boehringer Sohn AG & Co. KG in Global Neurodegenerative Disorder Therapeutics Market
           15.6.3    Financials
           15.6.4    Key Insight about Financial Health of the Company
           15.6.5    SWOT Analysis
15.7    Eisai Inc.
           15.7.1    Company Overview
           15.7.2    Role of Eisai Inc. in Global Neurodegenerative Disorder Therapeutics Market
           15.7.3    Financials
           15.7.4    Key Insight about Financial Health of the Company
           15.7.5    SWOT Analysis
15.8    F. Hoffmann-La Roche Ltd.
           15.8.1    Company Overview
           15.8.2    Role of F. Hoffmann-La Roche Ltd. in Global Neurodegenerative Disorder Therapeutics Market
           15.8.3    Financials
           15.8.4    Key Insights About Financial Health of the Company
           15.8.5    SWOT Analysis
15.9    GlaxoSmithKline plc
           15.9.1    Company Overview
           15.9.2    Role of GlaxoSmithKline plc in Global Neurodegenerative Disorder Therapeutics Market
           15.9.3    Financials
           15.9.4    Key Insights about Financial Health of the Company
           15.9.5    SWOT Analysis
15.10    H. Lundbeck A/S
             15.10.1    Company Overview
             15.10.2    Role of H. Lundbeck A/S in Global Neurodegenerative Disorder Therapeutics Market
             15.10.3    Financials
             15.10.4    Key Insight about Financial Health of the Company
             15.10.5    SWOT Analysis
15.11    Merck KGaA
             15.11.1    Company Overview
             15.11.2    Role of Merck KGaA in Global Neurodegenerative Disorder Therapeutics Market
             15.11.3    Financials
             15.11.4    Key Insights About Financial Health of the Company
             15.11.5    SWOT Analysis
15.12    Novartis AG
             15.12.1    Company Overview
             15.12.2    Role of Novartis AG in Global Neurodegenerative Disorder Therapeutics Market
             15.12.3    Financials
             15.12.4    Key Insights About Financial Health of the Company
             15.12.5    SWOT Analysis
15.13    Pfizer Inc.
             15.13.1    Company Overview
             15.13.2    Role of Pfizer Inc. in Global Neurodegenerative Disorder Therapeutics Market
             15.13.3    Financials
             15.13.4    Key Insights About Financial Health of the Company
             15.13.5    SWOT Analysis
15.14    Sanofi S.A.
             15.14.1    Company Overview
             15.14.2    Role of Sanofi SA in Global Neurodegenerative Disorder Therapeutics Market
             15.14.3    Financials
             15.14.4    Key Insights About Financial Health of the Company
             15.14.5    SWOT Analysis
15.15    Teva Pharmaceutical Industries Ltd.
             15.15.1    Company Overview
             15.15.2    Role of Teva Pharmaceutical Industries Ltd. in Global Neurodegenerative Disorder Therapeutics Market
             15.15.3    Financials
             15.15.4    Key Insight about Financial Health of the Company
             15.15.5    SWOT Analysis
15.16    UCB Pharma SA.
             15.16.1    Company Overview
             15.16.2    Role of UCB Pharma SA in Global Neurodegenerative Disorder Therapeutics Market
             15.16.3    Financials
             15.16.4    Key Insight about Financial Health of the Company
             15.16.5    SWOT Analysis

List of Tables

Table 1:    Leading Players in Global Neurodegenerative Disorder Therapeutics Market
Table 4.1:    Comparison of Drug Development Within and Outside the Central Nervous System
Table 4.2:    Commercialized Neurodegenerative Disorders Therapeutic Products
Table 8.1:    Regulatory Scenario Across the World
Table 8.2:    Expedited Regulatory Designations Around the World
Table 8.3:    Current Regulatory Development Guidelines for Neurodegenerative Disorders
Table 15.1:    AbbVie Inc.: Pipeline Product Portfolio
Table 15.2:    Biogen Inc.: Pipeline Product Portfolio
Table 15.3:    Bristol Myers Squibb Company: Pipeline Product Portfolio
Table 15.4:    C. H. Boehringer Sohn AG & Co. KG Company: Pipeline Product Portfolio
Table 15.5:    C. H. Boehringer Sohn AG & Co. KG Company: Pipeline Product Portfolio
Table 15.6:    F. Hoffmann-La Roche Ltd.: Pipeline Product Portfolio
Table 15.7:    H. Lundbeck A/S Company: Pipeline Product Portfolio
Table 15.8:    Merck KGaA: Pipeline Product Portfolio
Table 15.9:    Novartis AG: Pipeline Product Portfolio
Table 15.10:    Pfizer Plc: Pipeline Product Portfolio
Table 15.11:    Sanofi SA: Pipeline Product Portfolio
Table 15.12:    Teva Pharmaceutical Industries Ltd Company: Pipeline Product Portfolio
Table 15.13:    UCB Pharma SA Company: Pipeline Product Portfolio

List of Figures

Figure 1:    Global Total Burden of Diseases by Cause
Figure 2:    Global Geriatric Population by Age
Figure 3:    Global Neurodegenerative Disorder Therapeutics Market
Figure 4:    Impact Analysis
Figure 5:    Share of Key Developments and Strategies, June 2015-June 2020
Figure 6:    Global Neurodegenerative Disorder Therapeutics Market (by Drug Class),  2019 and 2030
Figure 7:    Global Neurodegenerative Disorder Therapeutics Market (by Indication),  2019 and 2030
Figure 8:    Global Neurodegenerative Disorder Therapeutics Market (by Route of Administraton), 2019 and 2030
Figure 9:    Global Neurodegenerative Disorder Therapeutics Market (by Region), 2019-2030
Figure 2.1:    Global Neurodegenerative Disorder Therapeutics Market Segmentation
Figure 3.1:    Global Neurodegenerative Disorder Therapeutic Market Methodology
Figure 3.2:    Primary Research Methodology
Figure 3.3:    Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.4:    Top-Down Approach (Segment-Wise Analysis)
Figure 4.1:    Neurodegenerative Disorder Therapeutics Clinical Trial Landscape
Figure 4.2:    Global Neurodegenerative Disorder Market 2019-2030
Figure 4.3:    Patent Expiry of Neurodegenerative Disorder Therapies
Figure 4.4:    Most Impacted Practices in the Treatment of Neurodegenerative Disorders
Figure 5.1:    Prevalence of Neurodegenerative Disorders in the U.S. (Total Population)
Figure 5.2:    Prevalence of Alzheimer’s Disease in the U.S. (Total Population)
Figure 5.3:    Prevalence of Epilepsy in the U.S. (Total Population)
Figure 5.4:    Prevalence of Parkinson’s Disease in the U.S. (Total Population)
Figure 5.5:    Prevalence of Multiple Sclerosis in the U.S. (Total Population)
Figure 5.6:    Prevalence of Spinal Muscular Atrophy (SMA) in the U.S. (Total Population)
Figure 5.7:    Prevalence of Huntington's Disease in the U.S. (Total Population)
Figure 5.8:    Target Population of Epilepsy in the U.S.
Figure 5.9:    Target Population of Alzheimer’s Disease in the U.S.
Figure 5.10:    Target Population of Multiple Sclerosis in the U.S.
Figure 5.11:    Target Population of Parkinson’s Disease in the U.S.
Figure 5.12:    Target Population of Huntington's Disease in the U.S.
Figure 6.1:    Number of Patents Filed, Neurodegenerative Disorder Therapeutics/Drugs, January 2015-December 2019
Figure 6.2:    Number of Patents Filed, Multiple Sclerosis Therapeutics/Drugs, January 2015-December 2019
Figure 6.3:    Number of Patents Filed, Alzheimer’s Disease Therapeutics/Drugs, January 2015-December 2019
Figure 6.4:    Percentage of Patents Filed, By Patent Office, January 2015-December 2019
Figure 7.1:    Impact Analysis
Figure 7.2:    Global Total Burden of Diseases by Cause
Figure 7.3:    Global Geriatric Population by Age
Figure 8.1:    Steps for Obtaining Marketing Authorization
Figure 8.2:    USFDA Review Timeline
Figure 8.3:    EMA Review Timeline
Figure 9.1:    Global Neurodegenerative Disorder Therapeutics Market (Tecfidera - Product Revenue), 2019-2030
Figure 9.2:    Global Neurodegenerative Disorder Therapeutics Market (Ocrevus – Product Revenue), 2019-2030
Figure 9.3:    Global Neurodegenerative Disorder Therapeutics Market (Gilenya – Product Revenue), 2019-2030
Figure 9.4:    Global Neurodegenerative Disorder Therapeutics Market (Aubagio – Product Revenue), 2019-2030
Figure 9.5:    Global Neurodegenerative Disorder Therapeutics Market (Interferon (Avonex and Plegridy) – Product Revenue), 2019-2030
Figure 9.6:    Global Neurodegenerative Disorder Therapeutics Market (Tysabri – Product Revenue), 2019-2030
Figure 9.7:    Global Neurodegenerative Disorder Therapeutics Market (Rebif – Product Revenue), 2019-2030
Figure 9.8:    Global Neurodegenerative Disorder Therapeutics Market (Copaxone – Product Revenue), 2019-2030
Figure 9.9:    Global Neurodegenerative Disorder Therapeutics Market (Betaseron – Product Revenue), 2019-2030
Figure 9.10:    Global Neurodegenerative Disorder Therapeutics Market (Lemtrada – Product Revenue), 2019-2030
Figure 9.11:    Global Neurodegenerative Disorder Therapeutics Market (Mavenclad – Product Revenue), 2019-2030
Figure 9.12:    Global Neurodegenerative Disorder Therapeutics Market (Fampyra – Product Revenue), 2019-2030
Figure 9.13:    Global Neurodegenerative Disorder Therapeutics Market (Ampyra – Product Revenue), 2019-2030
Figure 9.14:    Global Neurodegenerative Disorder Therapeutics Market (Mayzent – Product Revenue), 2019-2030
Figure 9.15:    Global Neurodegenerative Disorder Therapeutics Market (Vumerity – Product Revenue), 2019-2030
Figure 9.16:    Global Neurodegenerative Disorder Therapeutics Market (Others – Product Revenue), 2019-2030
Figure 9.17:    Global Neurodegenerative Disorder Therapeutics Market (Lyrica – Product Revenue), 2019-2030
Figure 9.18:    Global Neurodegenerative Disorder Therapeutics Market (Vimpat – Product Revenue), 2019-2030
Figure 9.19:    Global Neurodegenerative Disorder Therapeutics Market (Onfi – Product Revenue), 2019-2030
Figure 9.20:    Global Neurodegenerative Disorder Therapeutics Market (Keppra – Product Revenue), 2019-2030
Figure 9.21:    Global Neurodegenerative Disorder Therapeutics Market (Sabril – Product Revenue), 2019-2030
Figure 9.22:    Global Neurodegenerative Disorder Therapeutics Market (Briviact – Product Revenue), 2019-2030
Figure 9.23:    Global Neurodegenerative Disorder Therapeutics Market (Fycompa – Product Revenue), 2019-2030
Figure 9.24:    Global Neurodegenerative Disorder Therapeutics Market (Banzel – Product Revenue), 2019-2030
Figure 9.25:    Global Neurodegenerative Disorder Therapeutics Market (Others – Product Revenue), 2019-2030
Figure 9.26:    Global Neurodegenerative Disorder Therapeutics Market (Ebixa – Product Revenue), 2019-2030
Figure 9.27:    Global Neurodegenerative Disorder Therapeutics Market (Namenda XR – Product Revenue), 2019-2030
Figure 9.28:    Global Neurodegenerative Disorder Therapeutics Market (Namzaric – Product Revenue), 2019-2030
Figure 9.29:    Global Neurodegenerative Disorder Therapeutics Market (Galantamine – Product Revenue), 2019-2030
Figure 9.30:    Global Neurodegenerative Disorder Therapeutics Market (Others – Product Revenue), 2019-2030
Figure 9.31:    Global Neurodegenerative Disorder Therapeutics Market (Azilect – Product Revenue), 2019-2030
Figure 9.32:    Global Neurodegenerative Disorder Therapeutics Market (Neupro – Product Revenue), 2019-2030
Figure 9.33:    Global Neurodegenerative Disorder Therapeutics Market (Madopar – Product Revenue), 2019-2030
Figure 9.34:    Global Neurodegenerative Disorder Therapeutics Market (Duopa – Product Revenue), 2019-2030
Figure 9.35:    Global Neurodegenerative Disorder Therapeutics Market (Inbrija – Product Revenue), 2019-2030
Figure 9.36:    Global Neurodegenerative Disorder Therapeutics Market (Others – Product Revenue), 2019-2030
Figure 9.37:    Global Neurodegenerative Disorder Therapeutics Market (Spinraza – Product Revenue), 2019-2030
Figure 9.38:    Global Neurodegenerative Disorder Therapeutics Market (Zolgensma – Product Revenue), 2019-2030
Figure 9.39:    Global Neurodegenerative Disorder Therapeutics Market (Others – Product Revenue), 2019-2030
Figure 9.40:    Global Neurodegenerative Disorder Therapeutics Market (Austedo – Product Revenue),2019-2030
Figure 9.41:    Global Neurodegenerative Disorder Therapeutics Market (Xenazine – Product Revenue),2019-2030
Figure 9.42:    Global Neurodegenerative Disorder Therapeutics Market (Others – Product Revenue), 2019-2030
Figure 9.43:    Global Neurodegenerative Disorder Therapeutics Market (Zeposia Expected Launch - 2020), 2019-2030
Figure 9.44:    Global Neurodegenerative Disorder Therapeutics Market (Ponesimod Expected Launch - 2020), 2019-2030
Figure 9.45:    Global Neurodegenerative Disorder Therapeutics Market (Ofatumumab Expected Launch 2021), 2019-2030
Figure 9.46:    Global Neurodegenerative Disorder Therapeutics Market (Ublituximab Expected Launch - 2021), 2019-2030
Figure 9.47:    Global Neurodegenerative Disorder Therapeutics Market (Ibudilast Expected Launch - 2022), 2019-2030
Figure 9.48:    Global Neurodegenerative Disorder Therapeutics Market (SAR442168 Expected Launch - 2026), 2019-2030
Figure 9.49:    Global Neurodegenerative Disorder Therapeutics Market (Tricaprilin Expected Launch - 2023), 2019-2030
Figure 9.50:    Global Neurodegenerative Disorder Therapeutics Market (Bryostatin-1 Expected Launch - 2025), 2019-2030
Figure 9.51:    Global Neurodegenerative Disorder Therapeutics Market (AGB101 Expected Launch - 2025), 2019-2030
Figure 9.52:    Global Neurodegenerative Disorder Therapeutics Market (COR388 Expected Launch - 2023), 2019-2030
Figure 9.53:    Global Neurodegenerative Disorder Therapeutics Market (TRx0237 Expected Launch - 2024), 2019-2030
Figure 9.54:    Global Neurodegenerative Disorder Therapeutics Market (Brexpiprazole Expected Launch - 2023), 2019-2030
Figure 9.55:    Global Neurodegenerative Disorder Therapeutics Market (Semorinemab Expected Launch - 2024), 2019-2030
Figure 9.56:    Global Neurodegenerative Disorder Therapeutics Market (Aducanumab Expected Launch - 2020), 2019-2030
Figure 9.57:    Global Neurodegenerative Disorder Therapeutics Market (Eltoprazine Expected Launch - 2020), 2019-2030
Figure 9.58:    Global Neurodegenerative Disorder Therapeutics Market (Ongentys Expected Launch - 2020), 2019-2030
Figure 9.59:    Global Neurodegenerative Disorder Therapeutics Market (IPX-066 Expected Launch - 2020), 2019-2030
Figure 9.60:    Global Neurodegenerative Disorder Therapeutics Market (Xadago Expected Launch - 2020), 2019-2030
Figure 9.61:    Global Neurodegenerative Disorder Therapeutics Market (Nourianz Expected Launch - 2020), 2019-2030
Figure 9.62:    Global Neurodegenerative Disorder Therapeutics Market (Opicapone Expected Launch - 2020), 2019-2030
Figure 9.63:    Global Neurodegenerative Disorder Therapeutics Market (RG6042/IONIS -HTTrx Expected Launch - 2021), 2019-2030
Figure 9.64:    Global Neurodegenerative Disorder Therapeutics Market (WVE-120101 Expected Launch - 2022), 2019-2030
Figure 9.65:    Global Neurodegenerative Disorder Therapeutics Market (WVE-120102 Expected Launch - 2022), 2019-2030
Figure 10.1:    Revenue Contribution of Different Segments, 2019 and 2030
Figure 10.2:    Global Neurodegenerative Disorder Therapeutics Market (by Immunomodulators), 2019-2030
Figure 10.3:    Global Neurodegenerative Disorder Therapeutics Market (by Interferons), 2019-2030
Figure 10.4:    Global Neurodegenerative Disorder Therapeutics Market (by Dopamine agonists), 2019-2030
Figure 10.5:    Global Neurodegenerative Disorder Therapeutics Market (by Decarboxylase Inhibitors), 2019-2030
Figure 10.6:    Global Neurodegenerative Disorder Therapeutics Market (by Others), 2019-2030
Figure 11.1:    Global Neurodegenerative Disorder Therapeutics Market, by Indication
Figure 11.2:    Global Neurodegenerative Disorder Therapeutics Market (by Indication), 2020 and 2030
Figure 11.3:    Global Neurodegenerative Disorder Therapeutics Market (by Multiple Sclerosis), 2019-2030
Figure 11.4:    Global Neurodegenerative Disorder Therapeutics Market (by Epilepsy), 2019-2030
Figure 11.5:    Global Neurodegenerative Disorder Therapeutics Market (by Spinal Muscular Atrophy), 2019-2030
Figure 11.6:    Global Neurodegenerative Disorder Therapeutics Market (by Alzheimer’s disease), 2019-2030
Figure 11.7:    Global Neurodegenerative Disorder Therapeutics Market (by Parkinson’s disease), 2019-2030
Figure 11.8:    Global Neurodegenerative Disorder Therapeutics Market (by Huntington’s disease), 2019-2030
Figure 11.9:    Global Neurodegenerative Disorder Therapeutics Market (by Other Neurological Disorders), 2019-2030
Figure 12.1: Revenue Contribution of Different Segments, 2020 and 2030    
Figure 12.2: Global Neurodegenerative Disorder Therapeutics Market (by Oral), 2019-2030    
Figure 12.3: Global Neurodegenerative Disorder Therapeutics Market (by Injectable),  2019-2030    
Figure 12.4: Global Neurodegenerative Disorder Therapeutics Market (by Enteral),  2019-2030    
Figure 12.5: Global Neurodegenerative Disorder Therapeutics Market (by Transdermal),  2019-2030    
Figure 12.6: Global Neurodegenerative Disorder Therapeutics Market (by Other RoA), 2019-2030    
Figure 13.1:    Global Neurodegenerative Disorder Therapeutics Market (by Region)
Figure 13.2:    Global Neurodegenerative Disorder Therapeutics Market (by Region),  2019-2030
Figure 13.3:    North America Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.4:    North America: Market Dynamics
Figure 13.5:    Revenue Contributions of Different Countries in North America,  2019 and 2030
Figure 13.6:    U.S. Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.7:    U.S. Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
Figure 13.8:    Canada Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.9:    Canada Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
Figure 13.10:    Europe Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.11:    Europe: Market Dynamics
Figure 13.12:    Revenue Contributions Different Countries in Europe, 2019 and 2030
Figure 13.13:    Germany Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.14:    Germany Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
Figure 13.15:    U.K. Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.16:    U.K. Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
Figure 13.17:    France Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.18:    France Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
Figure 13.19:    Italy Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.20:    Italy Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
Figure 13.21:    Spain Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.22:    Spain Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
Figure 13.23:    Rest-of-Europe Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.24:    RoE Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
Figure 13.25:    Asia-Pacific Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.26:    APAC: Market Dynamics
Figure 13.27:    Revenue Contributions Different Countries in Asia-Pacific, 2019 and 2030
Figure 13.28:    China Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.29:    China Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
Figure 13.30:    Japan Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.31:    Japan Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
Figure 13.32:    India Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.33:    India Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
Figure 13.34:    South Korea Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.35:    South Korea Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
Figure 13.36:    Australia Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.37:    Australia Neurodegenerative Disorder Therapeutics Market (by Indication),  2019-2030
Figure 13.38:    RoAPAC Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.39:    RoAPAC Neurodegenerative Disorder Therapeutics Market (by Indication),  2019-2030
Figure 13.40:    Latin America Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.41:    Latin America Neurodegenerative Disorder Therapeutics Market (by Country), 2019-2030
Figure 13.42:    Revenue Contributions Different Countries in Latin America, 2019 and 2030
Figure 13.43:    Brazil Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.44:    Brazil Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
Figure 13.45:    Mexico Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.46:    Mexico Neurodegenerative Disorder Therapeutics Market (by Indication), 2019-2030
Figure 13.47:    Rest-of-Latin America Neurodegenerative Disorder Therapeutics Market, 2019-2030
Figure 13.48:    RoLATAM Neurodegenerative Disorder Therapeutics Market (by Indication),  2019-2030
Figure 13.49:    RoW Neurodegenerative disorder therapeutics market, 2019-2030
Figure 14.1: Share of Key Developments and Strategies,  July 2015 - July 2020    
Figure 14.2: Regulatory and Legal Developments Share (by Company),  July 2015 - July 2020    
Figure 14.3: Partnerships, Alliances, and Business Expansions (by Company),  July 2015 - July 2020    
Figure 14.4: M&A Activities Share (by Company), July 2015 - July 2020    
Figure 14.5: Market Share Analysis (by Companies), 2018 and 2019    
Figure 15.1:    Total Number of Companies Profiled
Figure 15.2:    AbbVie Inc.: Overall Product Portfolio
Figure 15.3:    AbbVie Inc.: Overall Financials, 2017-2019
Figure 15.4:    AbbVie Inc.: Revenue (by Region), 2017-2019
Figure 15.5:    AbbVie Inc.: R&D Expenditure, 2017-2019
Figure 15.6:    AbbVie Inc.: SWOT Analysis
Figure 15.7:    Bayer AG: Overall Product Portfolio
Figure 15.8:    Bayer AG: Overall Financials, 2017-2019
Figure 15.9:    Bayer AG: Revenue (by Segment), 2018-2019
Figure 15.10:    Bayer AG: Revenue (by Region), 2017-2019
Figure 15.11:    Bayer AG: R&D Expenditure, 2017-2019
Figure 15.12:    Bayer AG: SWOT Analysis
Figure 15.13:    Biogen Inc.: Overall Service Portfolio
Figure 15.14:    Biogen Inc.: Overall Financials, 2017-2019
Figure 15.15:    Biogen Inc.: Sales (by Product), 2017-2019
Figure 15.16:    Biogen Inc.: Sales (by Region), 2017-2019
Figure 15.17:    Biogen Inc.: R&D Expenditure, 2017-2019
Figure 15.18:    Biogen Inc.: SWOT Analysis
Figure 15.19:    Bristol Myers Squibb Company: Overall Product Portfolio
Figure 15.20:    Bristol Myers Squibb Company: Overall Financials, 2017-2019
Figure 15.21:    Bristol Myers Squibb Company: Revenue (by Region), 2017-2019
Figure 15.22:    Bristol Myers Squibb Company: R&D Expenditure, 2017-2019
Figure 15.23:    Bristol Myers Squibb Company: SWOT Analysis
Figure 15.24:    C. H. Boehringer Sohn AG & Co. KG: Overall Product Portfolio
Figure 15.25:    C. H. Boehringer Sohn AG & Co. KG: Overall Financials, 2017-2019
Figure 15.26:    C. H. Boehringer Sohn AG & Co. KG: Revenue (by Segment), 2017-2019
Figure 15.27:    C. H. Boehringer Sohn AG & Co. KG: Revenue (by Region), 2017-2019
Figure 15.28:    C. H. Boehringer Sohn AG & Co. KG: R&D Expenditure, 2017-2019
Figure 15.29:    C. H. Boehringer Sohn AG & Co. KG: SWOT Analysis
Figure 15.30:    Eisai Inc.: Overall Product Portfolio
Figure 15.31:    Eisai Inc.: Overall Financials, 2017-2019
Figure 15.32:    Eisai Inc.: Revenue (by Segment), 2017-2019
Figure 15.33:    Eisai Inc.: Revenue (by Region), 2017-2019
Figure 15.34:    Eisai Inc.: R&D Expenditure, 2017-2019
Figure 15.35:    Eisai Inc.: SWOT Analysis
Figure 15.36:    F. Hoffmann-La Roche Ltd: Product Portfolio
Figure 15.37:    F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019
Figure 15.38:    F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2017-2019
Figure 15.39:    F. Hoffmann-La Roche Ltd: Revenue (by Region), 2017-2019
Figure 15.40:    F. Hoffmann-La Roche Ltd: R&D Expenditure, 2017-2019
Figure 15.41:    F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 15.42:    GlaxoSmithKline plc: Overall Product Portfolio
Figure 15.43:    GlaxoSmithKline plc: Overall Financials, 2017-2019
Figure 15.44:    GlaxoSmithKline plc: Revenue (by Segment), 2017-2019
Figure 15.45:    GlaxoSmithKline plc: Revenue (by Region), 2017-2019
Figure 15.46:    GlaxoSmithKline plc: R&D Expenditure, 2017-2019
Figure 15.47:    GlaxoSmithKline plc: SWOT Analysis
Figure 15.48:    H. Lundbeck A/S: Overall Product Portfolio
Figure 15.49:    H. Lundbeck A/S: Overall Financials, 2017-2019
Figure 15.50:    H. Lundbeck A/S: Revenue (by Segment), 2017-2019
Figure 15.51:    H. Lundbeck A/S: Revenue (by Region), 2017-2019
Figure 15.52:    H. Lundbeck A/S: R&D Expenditure, 2017-2019
Figure 15.53:    H. Lundbeck A/S: SWOT Analysis
Figure 15.54:    Merck KGaA: Product Portfolio
Figure 15.55:    Merck KGaA: Overall Financials, 2017-2019
Figure 15.56:    Merck KGaA: Revenue (by Segment), 2017-2019
Figure 15.57:    Merck KGaA: Revenue (by Region), 2017-2019
Figure 15.58:    Merck KGaA: R&D Expenditure, 2017-2019
Figure 15.59:    Merck KGaA: SWOT Analysis
Figure 15.60:    Novartis AG: Overall Financials, 2017-2019
Figure 15.61:    Novartis AG Net Revenue (by Business Segment), 2017-2019
Figure 15.62:    Novartis AG: Net Revenue (by Region), 2017-2019
Figure 15.63:    Novartis AG: R& D Expense, 2017-2019
Figure 15.64:    Novartis AG: SWOT Analysis
Figure 15.65:    Pfizer Inc.: Overall Product Portfolio
Figure 15.66:    Pfizer Inc.: Overall Financials, 2017-2019
Figure 15.67:    Pfizer Inc.: Revenue (by Segment), 2017-2019
Figure 15.68:    Pfizer Inc.: Revenue Split (by Biopharma Segment), 2017-2019
Figure 15.69:    Pfizer Inc.: Revenue (by Region), 2017-2019
Figure 15.70:    Pfizer Inc: R&D Expenditure, 2017-2019
Figure 15.71:    Pfizer Inc.: SWOT Analysis
Figure 15.72:    Sanofi SA: Overall Product Portfolio
Figure 15.73:    Sanofi SA: Overall Financials, 2017-2019
Figure 15.74:    Sanofi SA: Revenue (by Segment), 2017-2019
Figure 15.75:    Sanofi SA: Revenue (by Region), 2017-2019
Figure 15.76:    Sanofi SA: R&D Expenditure, 2017-2019
Figure 15.77:    Sanofi SA: SWOT Analysis
Figure 15.78:    Teva Pharmaceutical Industries Ltd.: Overall Product Offerings for Global Neurodegenerative Disorder Therapeutics Market
Figure 15.79:    Teva Pharmaceutical Industries Ltd.: Overall Financials, 2017-2019
Figure 15.80:    Teva Pharmaceutical Industries Ltd.: Net Revenue (by Business Segment), 2017-2019
Figure 15.81:    Teva Pharmaceutical Industries Ltd.: Research and Development Expense, 2017-2019
Figure 15.82:    Teva Pharmaceutical Industries Ltd.: SWOT Analysis
Figure 15.83:    UCB Pharma SA: Overall Product Portfolio
Figure 15.84:    UCB Pharma SA: Overall Financials, 2017-2019
Figure 15.85:    UCB Pharma SA: Revenue (by Product), 2017-2019
Figure 15.86:    UCB Pharma SA: Revenue (by Region), 2017-2019
Figure 15.87:    UCB Pharma SA: R&D Expenditure, 2017-2019
Figure 15.88:    UCB Pharma SA: SWOT Analysis

FAQ's

Q. What is the expected growth of global neurodegenerative disorder therapeutics market in the coming years?

Answer: The neurodegenerative disorder therapeutics market is projected to grow at a CAGR of 7.21% during the forecast period, 2020-2030. The market is estimated to be around $48.91 Billion by the end of 2020.

Q. What are the key market drivers influencing the global neurodegenerative disorder therapeutics market?

Answer: The key driving factors that are promoting he growth of the market include rising global prevalence of neurodegenerative disorders, the increase in number of geriatric populations, increasing research funding in neurodegenerative disorders, and rising awareness about neurodegenerative disorders.

Q. What are the different strategies that are opted by the companies operating in the market to sustain competition?

Answer: The different strategies adopted by the companies operating in the market include regulatory and legal developments, partnerships, alliances, and business expansions, mergers and acquisition activities, and funding activities. Among all these activities regulatory and legal developments are leading the market.

Q. What are the possible indications for which global neurodegenerative disorder therapeutics can be used?

Answer: The neurodegenerative disorder therapeutics can be used for several health conditions, including multiple sclerosis, epilepsy, spinal muscular atrophy, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and other neurological disorders.

Q. Which are the top market players that are operating in the global neurodegenerative disorder therapeutics market?

Answer: The major companies operating in the market include Pfizer, Inc., Sanofi S.A., Novartis AG, UCB S.A., Teva Pharmaceutical Industries Ltd., F. Hoffmann- La Roche Ltd., H. Lundbeck A/S, GlaxoSmithKline PLC, Merk KGaA, AbbVie Inc., Boehringer Ingeiheim International GmbH, Bristol Myers Squibb Company, Bayer AG, and Eisai Co., Ltd.

You may also like

Published Year: 2021

Global Cell and Gene Therapy Market: Focus on Product Type, Therapeutic Class, Pipeline, Regional an

The global cell and gene therapy market was valued at $2,599.7 million in 2020, and it is...

 

Global Neurodegenerative Disorder Therapeutics Market

Focus on Product, Mechanism, Route of Administration, Indication, Country Data (14 Countries), and Competitive Landscape - Analysis and Forecast, 2019-2030